Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in Southeast Asia

American Journal of Epidemiology

Volumn 178, Issue 12, 2013, Pages 1740-1749

  Sun, Amanda Y ^a   Pai, Madhukar ^b,c   Salje, Henrik ^d   Satyanarayana, Srinath ^e   Deo, Sarang ^f   Dowdy, David W ^d,g  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^f INDIAN SCHOOL OF BUSINESS   (India)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Diagnostic techniques and procedures; Epidemiologic methods; Southeast Asia; Theoretical models; Tuberculosis

Indexed keywords

DISEASE CONTROL; DISEASE INCIDENCE; DISEASE TRANSMISSION; DISEASE TREATMENT; EPIDEMIOLOGY; MORTALITY; PRIVATE SECTOR; PUBLIC SECTOR; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ARTICLE; DIAGNOSTIC TEST; DISEASE TRANSMISSION; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; MOLECULAR DIAGNOSIS; MORTALITY; ORGANIZATION AND MANAGEMENT; POINT OF CARE TESTING; PREVALENCE; REINFECTION; SCREENING TEST; SENSITIVITY ANALYSIS; SOUTHEAST ASIA; SPUTUM SMEAR; TUBERCULOSIS; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

DIAGNOSTIC TECHNIQUES AND PROCEDURES; EPIDEMIOLOGIC METHODS; SOUTHEAST ASIA; THEORETICAL MODELS; TUBERCULOSIS;

ASIA, SOUTHEASTERN; COMPUTER SIMULATION; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HIV INFECTIONS; HUMANS; INCIDENCE; LIFE EXPECTANCY; MASS SCREENING; POINT-OF-CARE SYSTEMS; PREVALENCE; RESIDENCE CHARACTERISTICS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

SOUTHEAST ASIA;

EID: 84887389907     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt210     Document Type: Article

References (43)

1. World Health Organization. Global Tuberculosis Control: WHO Report 2012. Geneva, Switzerland: WHO Press; 2012.
2. Stop TB Partnership. The Global Plan to Stop TB 2011-2015: Transforming the Fight Towards Elimination of Tuberculosis. Geneva, Switzerland: WHO Press; 2011.
3. Cobelens F, van den Hof S, Pai M, et al. Which new diagnostics for tuberculosis, and when? J Infect Dis. 2012; 205(suppl 2):S191-S198.
4. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-1015.
5. Trébucq A, Enarson DA, Chiang CY, et al. Xpert MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis. 2011;15(12): 1567-1572.
6. Bill & Melinda Gates Foundation. Africa: Gates Foundation Invests in Cutting-Edge Research to Diagnose Tuberculosis in Developing Countries. Seattle, WA: Bill & Melinda Gates Foundation; 2012. (http://www.gatesfoundation.org/ pressreleases/Pages/research-to-diagnose-tuberculosis-120209. aspx). (Accessed December 28, 2012).
7. UNITAID. Tuberculosis Diagnostics Technology and Market Landscape. 2nd ed. Geneva, Switzerland: UNITAID; 2013. (http://www.unitaid.eu/images/ marketdynamics/publications/TB-Dx-Landscape-1-Jul-2013.pdf). (Accessed September 19, 2013).
8. Niemz A, Boyle DS. Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries. Expert Rev Mol Diagn. 2012;12(7):687-701.
9. World Health Organization. Global Tuberculosis Control: WHO Report 2011. Geneva, Switzerland: WHO Press; 2011.
10. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A. 2009;106(33):13980-13985.
11. Dowdy DW, Basu S, Andrews JR. Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. Am J Respir Crit Care Med. 2013;187(5):543-551.
12. Van Leth F, van der Werf MJ, Borgdorff M. Prevalence of tuberculosis infection and incidence of tuberculosis: a re-assessment of the Styblo rule. Bull World Health Organ. 2008;86(1):20-26.
13. Andrews JR, Noubary F, Walensky RP, et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Am J Epidemiol. 2012;54(6): 784-791.
14. Mahendradhata Y, Syahrizal BM, Utarini A. Delayed treatment of tuberculosis patients in rural areas of Yogyakarta province, Indonesia. BMC Public Health. 2008;8:393.
15. Rajeswari R, Chandrasekaran V, Suhadev M, et al. Factors associated with patient and health system delays in the diagnosis of tuberculosis in South India. Int J Tuberc Lung Dis. 2002;6(9):789-795.
16. Nair N, Wares F, Sahu S. Tuberculosis in the WHO South-East Asia Region. Bull World Health Organ. 2010;88(3):164.
17. World Bank. Tuberculosis Treatment Success Rate (% of Registered Cases). Washington, DC:World Bank Group; 2012. (http://data.worldbank.org/indicator/SH. TBS.CURE. ZS). (Accessed December 28, 2012).
18. Lonnroth K, Thuong LM, Lambregts K, et al. Private tuberculosis care provision associated with poor treatment outcome: comparative study of a semi-private lung clinic and the NTP in two urban districts in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis. 2003;7:165-171.
19. Chengsorn N, Bloss E, Anekvorapong R, et al. Tuberculosis services and treatment outcomes in private and public health care facilities in Thailand, 2004-2006. Int J Tuberc Lung Dis. 2009;13(7):888-894.
20. Bhargava A, Pinto L, Pai M. Mismanagement of tuberculosis in India: causes, consequences, and the way forward. Hypothesis. 2011;9(1):e7.
21. van Cleeff M, Kivihya-Ndugga LE, Meme H, et al. The role and performance of chest x-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi, Kenya. BMC Infect Dis. 2005;5:111.
22. Steingart KR, Flores LL, Dendukuri N, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med. 2011;8(8):e1001062.
23. Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the Global AIDS Epidemic 2010. HIV Prevalence Map. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2010. (http://www.unaids.org/globalreport/HIV- prevalence-map.htm). (Accessed December 28, 2012).
24. Botha E, Den Boon S, Verver S, et al. Initial default from tuberculosis treatment: how often does it happen and what are the reasons? Int J Tuberc Lung Dis. 2008;12(7):820-823.
25. Khan MS, Khan S, Godfrey-Faussett P. Default during TB diagnosis: quantifying the problem. Trop Med Int Health. 2009;14(12):1437-1441.
26. World Health Organization. Systematic Screening for Active Tuberculosis: Principles and Recommendations. Geneva, Switzerland: WHO Press; 2013.
27. Verver S, Warren RM, Munch Z, et al. Proportion of tuberculosis transmission that takes place in households in a high-incidence area. Lancet. 2004;363(9404):212-214.
28. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature. 2006;444(suppl 1):49-57.
29. Dowdy DW, Chaisson RE, Moulton LH, et al. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS. 2006;20(5):751-762.
30. Lin HH, Dowdy DW, Dye C, et al. The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ. 2012;90(10):739-747A.
31. Menzies NA, Cohen T, Lin HH, et al. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347.
32. Sachdeva KS, Kumar A, Dewan P, et al. New vision for Revised National Tuberculosis Control Programme (RNTCP): universal access-"reaching the un-reached." Ind J Med Res. 2012;135(5):690-694.
33. Vynnycky E, Fine PEM. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect. 1997;119(2):183-201.
34. Sutherland I, Svandova E, Radhakrishna S. The development of clinical tuberculosis following infection with tubercule bacilli. Tubercle. 1982;63(4):255-268.
35. Behr MA, Warren SA, Salomon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999;353(9151):444-449.
36. Sergeev R, Colijn C, Murray M, et al. Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med. 2012;4(135):135ra67.
37. Horsburgh CR, O'Donnell M, Chamblee S, et al. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med. 2010;182(3):420-425.
38. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007;369(9578): 2042-2049.
39. World Bank. Population, Total. Washington, DC: World Bank Group; 2012. (http://data.worldbank.org/indicator/SP.POP. TOTL). (Accessed December 28, 2012).
40. Tiemersma EW, van der Werf MJ, Borgdorff MW, et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PloS One. 2011;6(4):e17601.
41. International Fund for Agricultural Development. Rural Poverty Report 2011. Rome, Italy: International Fund for Agricultural Development; 2010. (http://www.ifad.org/rpr2011/). (Accessed December 28, 2012).
42. World Bank. Agriculture & Rural Development. Washington, DC:World Bank Group; 2012. (http://data.worldbank.org/topic/agriculture-and-rural- development). (Accessed December 28, 2012).
43. Dowdy DW, Lourenço MC, Cavalcante SC, et al. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PloS One. 2008;3(12): e4057.